Chongqing Lummy Pharmaceutical Co., Ltd. (300006.SZ)
CNY 5.25
(-2.42%)
CNY 5.25
(-2.42%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.92 Million CNY | 87.01% |
| 2022 | -68.7 Million CNY | 31.65% |
| 2021 | -100.52 Million CNY | 69.24% |
| 2020 | -326.76 Million CNY | -110.55% |
| 2019 | -155.19 Million CNY | -258.36% |
| 2018 | 98 Million CNY | 76.39% |
| 2017 | 55.56 Million CNY | 695.88% |
| 2016 | 6.98 Million CNY | -66.13% |
| 2015 | 20.61 Million CNY | 122.15% |
| 2014 | 9.27 Million CNY | -84.74% |
| 2013 | 60.8 Million CNY | 13.21% |
| 2012 | 53.71 Million CNY | -26.51% |
| 2011 | 73.09 Million CNY | 66.61% |
| 2010 | 43.86 Million CNY | 8.4% |
| 2009 | 40.46 Million CNY | 23.05% |
| 2008 | 32.88 Million CNY | 34.27% |
| 2007 | 24.49 Million CNY | 186.7% |
| 2006 | 8.54 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 5.9 Million CNY | 229.03% |
| 2024 Q3 | -27.74 Million CNY | -569.98% |
| 2024 Q1 | -4.57 Million CNY | -110.04% |
| 2023 Q3 | -456.92 Thousand CNY | 99.09% |
| 2023 Q4 | 45.58 Million CNY | 10076.7% |
| 2023 Q2 | -50.42 Million CNY | -1287.51% |
| 2023 FY | -8.92 Million CNY | 87.01% |
| 2023 Q1 | -3.63 Million CNY | 88.4% |
| 2022 Q1 | -26.4 Million CNY | 78.09% |
| 2022 Q2 | -22.66 Million CNY | 14.15% |
| 2022 Q3 | 11.69 Million CNY | 151.61% |
| 2022 Q4 | -31.33 Million CNY | -367.86% |
| 2022 FY | -68.7 Million CNY | 31.65% |
| 2021 Q4 | -120.49 Million CNY | -869.91% |
| 2021 FY | -100.52 Million CNY | 69.24% |
| 2021 Q2 | -16.51 Million CNY | -133.77% |
| 2021 Q3 | -12.42 Million CNY | 24.77% |
| 2021 Q1 | 48.9 Million CNY | 114.94% |
| 2020 Q2 | 16.25 Thousand CNY | 100.2% |
| 2020 Q4 | -327.3 Million CNY | -3884.69% |
| 2020 Q1 | -8.11 Million CNY | 96.49% |
| 2020 FY | -326.76 Million CNY | -110.55% |
| 2020 Q3 | 8.64 Million CNY | 53103.63% |
| 2019 Q3 | 22.17 Million CNY | -32.9% |
| 2019 FY | -155.19 Million CNY | -258.36% |
| 2019 Q1 | 20.81 Million CNY | 1129.82% |
| 2019 Q2 | 33.05 Million CNY | 58.8% |
| 2019 Q4 | -231.24 Million CNY | -1142.62% |
| 2018 FY | 98 Million CNY | 76.39% |
| 2018 Q4 | -2.02 Million CNY | -110.49% |
| 2018 Q3 | 19.26 Million CNY | -45.25% |
| 2018 Q2 | 35.19 Million CNY | -22.76% |
| 2018 Q1 | 45.56 Million CNY | 928.11% |
| 2017 Q1 | 21.87 Million CNY | 154.78% |
| 2017 Q3 | 17.62 Million CNY | -18.25% |
| 2017 FY | 55.56 Million CNY | 695.88% |
| 2017 Q4 | -5.5 Million CNY | -131.21% |
| 2017 Q2 | 21.56 Million CNY | -1.42% |
| 2016 FY | 6.98 Million CNY | -66.13% |
| 2016 Q1 | 19.24 Million CNY | 195.41% |
| 2016 Q2 | 13.07 Million CNY | -32.07% |
| 2016 Q3 | 14.59 Million CNY | 11.6% |
| 2016 Q4 | -39.92 Million CNY | -373.67% |
| 2015 Q2 | 5.39 Million CNY | -4.7% |
| 2015 Q1 | 5.66 Million CNY | -78.14% |
| 2015 Q3 | 3.03 Million CNY | -43.87% |
| 2015 FY | 20.61 Million CNY | 122.15% |
| 2015 Q4 | 6.51 Million CNY | 114.95% |
| 2014 Q3 | 8.31 Million CNY | 300.97% |
| 2014 Q4 | 25.92 Million CNY | 211.99% |
| 2014 Q2 | -4.13 Million CNY | 80.14% |
| 2014 Q1 | -20.82 Million CNY | -217.27% |
| 2014 FY | 9.27 Million CNY | -84.74% |
| 2013 Q4 | 17.75 Million CNY | 207.06% |
| 2013 Q3 | 5.78 Million CNY | -64.11% |
| 2013 Q2 | 16.11 Million CNY | -23.82% |
| 2013 Q1 | 21.15 Million CNY | 183.48% |
| 2013 FY | 60.8 Million CNY | 13.21% |
| 2012 FY | 53.71 Million CNY | -26.51% |
| 2012 Q3 | 12.51 Million CNY | -22.96% |
| 2012 Q2 | 16.24 Million CNY | -7.12% |
| 2012 Q4 | 7.46 Million CNY | -40.38% |
| 2012 Q1 | 17.48 Million CNY | 48.5% |
| 2011 Q2 | 27.5 Million CNY | 34.53% |
| 2011 FY | 73.09 Million CNY | 66.61% |
| 2011 Q1 | 20.44 Million CNY | 49.28% |
| 2011 Q4 | 11.77 Million CNY | -11.88% |
| 2011 Q3 | 13.36 Million CNY | -51.4% |
| 2010 Q1 | 10.99 Million CNY | -9.43% |
| 2010 Q3 | 8.13 Million CNY | -26.3% |
| 2010 Q4 | 13.69 Million CNY | 68.32% |
| 2010 FY | 43.86 Million CNY | 8.4% |
| 2010 Q2 | 11.03 Million CNY | 0.39% |
| 2009 FY | 40.46 Million CNY | 23.05% |
| 2009 Q4 | 12.14 Million CNY | 17.44% |
| 2009 Q3 | 10.33 Million CNY | 23.4% |
| 2009 Q2 | 8.37 Million CNY | -12.81% |
| 2009 Q1 | 9.6 Million CNY | -15.94% |
| 2008 FY | 32.88 Million CNY | 34.27% |
| 2008 Q4 | 11.43 Million CNY | 43.92% |
| 2008 Q3 | 7.94 Million CNY | 0.0% |
| 2007 FY | 24.49 Million CNY | 186.7% |
| 2006 FY | 8.54 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 488.73 Million CNY | 101.827% |
| Zhejiang Zhenyuan Share Co., Ltd. | 81.64 Million CNY | 110.935% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -215.14 Million CNY | 95.851% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -140.24 Million CNY | 93.635% |
| Yifan Pharmaceutical Co., Ltd. | -551.07 Million CNY | 98.38% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 34.32 Million CNY | 126.012% |
| Sichuan Kelun Pharmaceutical Co., Ltd. | 2.45 Billion CNY | 100.363% |
| Boai NKY Medical Holdings Ltd. | 493.02 Million CNY | 101.811% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 310.18 Million CNY | 102.878% |